EGFR and non-small cell lung carcinoma: In summary, our work has revealed an essential role of Topo IIα modulation in regulating the responses of EGFRm NSCLC cells to osimertinib; this provides a strong scientific rationale for managing acquired resistance to osimertinib and possibly other third-generation EGFR-TKIs via targeting Topo II.